[go: up one dir, main page]

RU2009108149A - Иммуноглобулины - Google Patents

Иммуноглобулины Download PDF

Info

Publication number
RU2009108149A
RU2009108149A RU2009108149/10A RU2009108149A RU2009108149A RU 2009108149 A RU2009108149 A RU 2009108149A RU 2009108149/10 A RU2009108149/10 A RU 2009108149/10A RU 2009108149 A RU2009108149 A RU 2009108149A RU 2009108149 A RU2009108149 A RU 2009108149A
Authority
RU
Russia
Prior art keywords
hosm
site
osmrβ
lifr
modulates
Prior art date
Application number
RU2009108149/10A
Other languages
English (en)
Inventor
Джонатан Генри ЭЛЛИС (GB)
Джонатан Генри Эллис
Александр ЭОН-ДЮВАЛЬ (GB)
Александр ЭОН-ДЮВАЛЬ
Фолькер ГЕРМАШЕВСКИ (GB)
Фолькер Гермашевски
Кристофер ПЛАМПТОН (GB)
Кристофер ПЛАМПТОН
Николас Тимоти РЭПСОН (GB)
Николас Тимоти РЭПСОН
Майкл Роберт УЭСТ (GB)
Майкл Роберт УЭСТ
Original Assignee
Глаксо Груп Лимитед (GB)
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0407197A external-priority patent/GB0407197D0/en
Priority claimed from GB0407193A external-priority patent/GB0407193D0/en
Application filed by Глаксо Груп Лимитед (GB), Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед (GB)
Publication of RU2009108149A publication Critical patent/RU2009108149A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

1. Фармацевтическая композиция, содержащая биспецифичное терапевтическое антитело, которое связывает онкотатин М человека (hOSM) и модулирует взаимодействие как между (а) сайтом II hOSM и gp130, так и между (б) сайтом III hOSM и β-рецептором для онкостатина М (OSMRβ) и/или рецептором фактора ингибирования лейкоза (LIFR), в терапевтически эффективном количестве. ! 2. Фармацевтическая композиция, содержащая по меньшей мере первый антагонист, который связывает hOSM и модулирует взаимодействие как между (а) сайтом II hOSM и gp130, так и между (б) сайтом III hOSM и OSMRβ и/или LIFR.

Claims (2)

1. Фармацевтическая композиция, содержащая биспецифичное терапевтическое антитело, которое связывает онкотатин М человека (hOSM) и модулирует взаимодействие как между (а) сайтом II hOSM и gp130, так и между (б) сайтом III hOSM и β-рецептором для онкостатина М (OSMRβ) и/или рецептором фактора ингибирования лейкоза (LIFR), в терапевтически эффективном количестве.
2. Фармацевтическая композиция, содержащая по меньшей мере первый антагонист, который связывает hOSM и модулирует взаимодействие как между (а) сайтом II hOSM и gp130, так и между (б) сайтом III hOSM и OSMRβ и/или LIFR.
RU2009108149/10A 2004-03-30 2009-03-10 Иммуноглобулины RU2009108149A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0407197.3 2004-03-30
GB0407197A GB0407197D0 (en) 2004-03-30 2004-03-30 Immunoglobulins
GB0407193A GB0407193D0 (en) 2004-03-30 2004-03-30 Immunoglobulins
GB0407193.2 2004-03-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2006134477/10A Division RU2429245C2 (ru) 2004-03-30 2005-03-29 Иммуноглобулины

Publications (1)

Publication Number Publication Date
RU2009108149A true RU2009108149A (ru) 2010-09-20

Family

ID=35064447

Family Applications (5)

Application Number Title Priority Date Filing Date
RU2006134477/10A RU2429245C2 (ru) 2004-03-30 2005-03-29 Иммуноглобулины
RU2009108148/10A RU2009108148A (ru) 2004-03-30 2009-03-10 Иммуноглобулины
RU2009108149/10A RU2009108149A (ru) 2004-03-30 2009-03-10 Иммуноглобулины
RU2009108147/10A RU2009108147A (ru) 2004-03-30 2009-03-10 Иммуноглобулины
RU2011121419/10A RU2011121419A (ru) 2004-03-30 2011-05-30 Иммуноглобулины

Family Applications Before (2)

Application Number Title Priority Date Filing Date
RU2006134477/10A RU2429245C2 (ru) 2004-03-30 2005-03-29 Иммуноглобулины
RU2009108148/10A RU2009108148A (ru) 2004-03-30 2009-03-10 Иммуноглобулины

Family Applications After (2)

Application Number Title Priority Date Filing Date
RU2009108147/10A RU2009108147A (ru) 2004-03-30 2009-03-10 Иммуноглобулины
RU2011121419/10A RU2011121419A (ru) 2004-03-30 2011-05-30 Иммуноглобулины

Country Status (24)

Country Link
US (2) US7858753B2 (ru)
EP (2) EP2404935A1 (ru)
JP (1) JP4809828B2 (ru)
KR (1) KR100942849B1 (ru)
AR (1) AR048516A1 (ru)
AT (1) ATE515515T1 (ru)
AU (1) AU2005229457B2 (ru)
BR (1) BRPI0509367A (ru)
CA (1) CA2562953A1 (ru)
CY (1) CY1112192T1 (ru)
DK (1) DK1730191T3 (ru)
HR (1) HRP20110657T1 (ru)
IL (1) IL178119A0 (ru)
MA (1) MA28541B1 (ru)
NO (1) NO20064886L (ru)
NZ (1) NZ550225A (ru)
PE (1) PE20060287A1 (ru)
PL (1) PL1730191T3 (ru)
PT (1) PT1730191E (ru)
RU (5) RU2429245C2 (ru)
SG (1) SG151292A1 (ru)
SI (1) SI1730191T1 (ru)
TW (1) TWI365746B (ru)
WO (1) WO2005095457A2 (ru)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
WO2007098547A1 (en) * 2006-03-01 2007-09-07 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
CA2652733C (en) 2006-05-25 2016-06-21 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
PL2305300T3 (pl) 2008-07-10 2016-09-30 Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi
PL2322221T3 (pl) 2008-08-05 2015-01-30 Toray Industries Kompozycja farmaceutyczna do leczenia i zapobiegania raka
WO2010027797A1 (en) * 2008-08-26 2010-03-11 Macrogenics Inc. T-cell receptor antibodies and methods of use thereof
US8309688B2 (en) 2008-12-30 2012-11-13 Centocor Ortho Biotech Inc. Monkey homolog of human oncostatin M and methods of use thereof
EP2258723A1 (en) * 2009-06-02 2010-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Treatment of oncostatin M receptor ß mediated heart failure
EP2532365B1 (en) 2010-02-04 2016-05-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
PT2532366T (pt) 2010-02-04 2016-12-20 Toray Industries Composição farmacêutica para o tratamento e/ou prevenção de cancro
MX340016B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CN102822335B (zh) 2010-02-04 2015-09-30 东丽株式会社 癌的治疗和/或预防用药物组合物
DK2532680T3 (da) 2010-02-04 2015-07-20 Toray Industries Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
WO2012051111A2 (en) 2010-10-13 2012-04-19 Janssen Biotech, Inc. Human oncostatin m antibodies and methods of use
SMT201800397T1 (it) * 2010-11-23 2018-09-13 Glaxo Group Ltd Proteine leganti l'antigene per oncostatina m (osm)
PL2740794T3 (pl) 2011-08-04 2018-09-28 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub profilaktyki nowotworów
CN103764825B (zh) 2011-08-04 2015-09-02 东丽株式会社 癌的治疗和/或预防用药物组合物
US9180188B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
DK2818482T3 (da) 2012-02-21 2019-07-15 Toray Industries Farmaceutisk sammensætning til behandling af cancer
ES2643241T3 (es) 2012-02-21 2017-11-21 Toray Industries, Inc. Composición medicinal para tratar y/o prevenir el cáncer
ES2739380T3 (es) 2012-02-21 2020-01-30 Toray Industries Composición farmacéutica para el tratamiento del cáncer
MX363136B (es) 2012-02-21 2019-03-12 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
JP6107655B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 胆嚢癌の治療及び／又は予防用医薬組成物
RU2640245C2 (ru) 2012-03-30 2017-12-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или предотвращения рака печени
NZ753995A (en) 2013-05-30 2022-07-01 Kiniksa Pharmaceuticals Ltd Oncostatin m receptor antigen binding proteins
CA2918989C (en) 2013-08-09 2021-11-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
US9550828B2 (en) 2013-09-05 2017-01-24 Boise State University Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
NZ760008A (en) * 2014-02-24 2023-03-31 Takeda Pharmaceuticals Co Uti fusion proteins
US20170327573A1 (en) * 2014-09-24 2017-11-16 Universitá Degli Studi Di Padova Composition to induce bone marrow stem cell mobilization
JP6787904B2 (ja) * 2015-01-29 2020-11-18 アレス トレーディング ソシエテ アノニム 高度に正に荷電したタンパク質のイムノアッセイ
RU2767329C2 (ru) 2016-02-06 2022-03-17 Эпимаб Биотерапьютикс, Инк. Иммуноглобулин с тандемными fab-фрагментами и варианты его применения
BR112018069318A2 (pt) 2016-03-28 2019-01-22 Toray Industries composição farmacêutica para tratamento e/ou prevenção de um câncer, anticorpo ou fragmento do mesmo, combinação farmacêutica para tratamento e/ou prevenção de um câncer e método para tratar e/ou prevenir um câncer
GB201614627D0 (en) * 2016-08-30 2016-10-12 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
AU2019263850A1 (en) 2018-05-03 2020-11-19 Shanghai Epimab Biotherapeutics Co., Ltd. High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom
FR3090637A1 (fr) * 2018-12-21 2020-06-26 Universite De Poitiers Protéine de liaison spécifique capable de se lier spécifiquement à l’oncostatine M humaine (hOSM) et ses utilisations.
US11633457B2 (en) 2019-04-11 2023-04-25 Boise State University Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use
US12180290B2 (en) 2020-10-19 2024-12-31 Zoetis Services Llc Antibodies to canine and feline oncostatin M receptor beta and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DK1266965T3 (da) 1991-07-25 2006-09-25 Biogen Idec Inc Rekombinante antistoffer til human terapi
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
DK0703925T3 (da) 1993-06-03 1999-12-06 Therapeutic Antibodies Inc Fremstilling af antistoffragmenter
JP3622208B2 (ja) 1993-06-11 2005-02-23 東ソー株式会社 骨粗鬆症治療方法及び治療薬
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
JP2002512776A (ja) 1998-04-28 2002-05-08 スミスクライン・ビーチャム・コーポレイション 免疫原性の低下したモノクローナル抗体
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells

Also Published As

Publication number Publication date
EP1730191B1 (en) 2011-07-06
EP1730191A2 (en) 2006-12-13
JP2007530068A (ja) 2007-11-01
RU2011121419A (ru) 2012-12-10
JP4809828B2 (ja) 2011-11-09
BRPI0509367A (pt) 2007-09-11
IL178119A0 (en) 2006-12-31
US20070286861A1 (en) 2007-12-13
DK1730191T3 (da) 2011-10-17
CA2562953A1 (en) 2005-10-13
SI1730191T1 (sl) 2011-11-30
EP2404935A1 (en) 2012-01-11
NO20064886L (no) 2006-12-12
TWI365746B (en) 2012-06-11
PT1730191E (pt) 2011-10-04
ATE515515T1 (de) 2011-07-15
SG151292A1 (en) 2009-04-30
HK1103747A1 (en) 2007-12-28
RU2429245C2 (ru) 2011-09-20
WO2005095457A2 (en) 2005-10-13
HRP20110657T1 (hr) 2011-10-31
AU2005229457B2 (en) 2010-11-25
US20110245470A1 (en) 2011-10-06
MA28541B1 (fr) 2007-04-03
NZ550225A (en) 2010-11-26
US7858753B2 (en) 2010-12-28
RU2009108147A (ru) 2010-09-20
PE20060287A1 (es) 2006-05-16
RU2009108148A (ru) 2010-09-20
CY1112192T1 (el) 2015-12-09
WO2005095457A3 (en) 2006-04-27
TW200602079A (en) 2006-01-16
KR20060135049A (ko) 2006-12-28
PL1730191T3 (pl) 2011-12-30
RU2006134477A (ru) 2008-05-10
KR100942849B1 (ko) 2010-02-17
AU2005229457A1 (en) 2005-10-13
AR048516A1 (es) 2006-05-03

Similar Documents

Publication Publication Date Title
RU2009108149A (ru) Иммуноглобулины
UA90457C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms
ATE389721T1 (de) Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen
EA201300022A1 (ru) Терапевтическое человеческое моноклональное антитело против il-1r1
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
ATE465181T1 (de) Humanisierte anti-cmet-antagonisten
EA200501810A1 (ru) Композиция конъюгированного лекарственного средства
ECSP066468A (es) Antagonistas de receptores muscarínicos de acetilcolina
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
ATE457740T1 (de) Pharmazeutische zubereitung enthaltend einen antikörper gegen den rezeptor für einen epidermalen wachstumsfaktor (egf-rezeptor)
DE60130256D1 (de) Naphthalinderivate, die sich an den ep4?rezeptor binden
TR200401264T4 (tr) CB1-reseptör-antagonistiyle-sibütramin birleşimi, bunları içeren farmasötik-bileşimler ve obezite tedavisinde kullanımları.
NO20053101L (no) Kimaere og humaniserte antistoffer motalfa-5beta-1 integrin som modulerer angiogenese.
CY1104993T1 (el) 4-(πιπεριδυλ- και πυρρολιδινυλ-αλκυλ-ουρεϊδο)-κινολινες ως ανταγωνιστες του υποδοχεα ουροτασινης ii
DE60234616D1 (de) Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
CY1106927T1 (el) Φαρμακευτικη συνθεση ενος pde4 ή pde3/4 αναστολεα και ανταγωνιστη υποδοχεα ισταμινης
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
EP1354896A4 (en) NEW MONOCLONAL ANTIBODY
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
TR200200913T2 (tr) Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları.
EP2641611A3 (en) Combination therapy

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20121107